Almirall Showcases New Biologics Data for Psoriasis and Atopic Dermatitis at EADV Congress, Celebrating 80 Years of Innovation

Almirall, S.A. (ALM), a global leader in medical dermatology, will participate in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam from September 25 to 28, 2024. This year also marks Almirall’s 80th anniversary, celebrating…

Read MoreAlmirall Showcases New Biologics Data for Psoriasis and Atopic Dermatitis at EADV Congress, Celebrating 80 Years of Innovation

ImageBloom Launches First-of-Its-Kind Patient Recruitment Marketplace for Clinical Research

ImageBloom, Inc., a leader in clinical trial support solutions, is thrilled to announce the launch of the Patient Recruitment Marketplace. This groundbreaking platform is set to transform patient recruitment for clinical research sites. It allows research teams to quickly access…

Read MoreImageBloom Launches First-of-Its-Kind Patient Recruitment Marketplace for Clinical Research

True You Weight Loss Becomes First U.S. Practice to Perform 5,000 Endoscopic Weight Loss Procedures

Gastroenterologist and obesity medicine specialist Dr. Christopher McGowan performed the 5,000th endobariatric weight loss procedure this week at True You Weight Loss, marking the practice as the first in the nation to achieve this notable milestone. Endobariatrics: A New Approach…

Read MoreTrue You Weight Loss Becomes First U.S. Practice to Perform 5,000 Endoscopic Weight Loss Procedures

Aditxt’s Pearsanta Partners with Evofem for U.S. Endometriosis Diagnostic Launch in Mid-2025

Aditxt, Inc. (NASDAQ: ADTX), an innovation platform aimed at accelerating health advancements, has announced that its majority-owned subsidiary, Pearsanta, Inc., has entered into a Market Development Collaboration Agreement with Evofem Biosciences, a leader in women’s health. This partnership will focus…

Read MoreAditxt’s Pearsanta Partners with Evofem for U.S. Endometriosis Diagnostic Launch in Mid-2025

Debiopharm Honors Innovative Japanese Cancer Research at 83rd Japanese Cancer Association Meeting

Debiopharm Honors Recipients of 2024 JCA-Mauvernay Award for Breakthrough Cancer Research Debiopharm, a Swiss-based biopharmaceutical company focused on advancing cancer and infectious disease treatments, has announced the winners of the 2024 JCA-Mauvernay Award, celebrating its 20th edition. The award recognizes…

Read MoreDebiopharm Honors Innovative Japanese Cancer Research at 83rd Japanese Cancer Association Meeting

AngioDynamics Launches RECOVER-AV Trial for AlphaVac F18⁸⁵ System in Pulmonary Embolism Treatment

AngioDynamics, Inc. (NASDAQ: ANGO), a leading medical technology company dedicated to enhancing vascular health and expanding cancer treatment options, has announced the launch of the RECOVER-AV trial. This prospective, multicenter, multinational, single-arm study will evaluate the efficacy, safety, and long-term…

Read MoreAngioDynamics Launches RECOVER-AV Trial for AlphaVac F18⁸⁵ System in Pulmonary Embolism Treatment

Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR Positive, HER2 Low/Negative Breast Cancer: TROPION-Breast01 Phase 3 Trial

Topline Results from TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan The TROPION-Breast01 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) against investigator’s choice chemotherapy has reported that while the treatment met its primary endpoint for progression-free survival (PFS), it did not…

Read MoreFinal Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR Positive, HER2 Low/Negative Breast Cancer: TROPION-Breast01 Phase 3 Trial